Therapy Detail

Therapy Name Rituximab
Therapy Description

Rituxan (rituximab) is a chimeric mononclonal CD20-targeted antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent cytotoxicity and antibody-dependent cellular cytoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use in non-Hodgkin lymphoma and chronic lymphocytic leukemia (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Rituximab Rituxan IDEC-C2B8 CD20 Antibody 3 Rituxan (rituximab) is a chimeric mononclonal CD20-targeted antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent cytotoxicity and antibody-dependent cellular cytoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use in non-Hodgkin lymphoma and chronic lymphocytic leukemia (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown follicular lymphoma not applicable Rituximab Phase III Actionable In a Phase III trial, Rituxan (rituximab) treatment in patients with follicular lymphoma resulted in an overall survival of 84.9% in patients receiving the drug intravenously and 84.4% in patients receiving the drug subcutaneously (PMID: 28476440). 28476440
Unknown unknown non-Hodgkin lymphoma not applicable Rituximab FDA approved Actionable In a clinical trial that supported FDA approval, treatment with Rituxan (rituximab) resulted in a response rate of 48% in patients (n=166) with relapsed low-grade or follicular non-Hodgkin lymphoma (PMID: 9704735). 9704735
Unknown unknown central nervous system lymphoma not applicable Rituximab Clinical Study Actionable In a meta-analysis of 580 patients, intravenous Rituximab treatment correlated with overall survival (HR=0.498, p<0.001) in patients with primary central nervous system lymphoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 333PD). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Not yet recruiting
NCT02406742 Phase Ib/II Obinutuzumab Rituximab Ibrutinib CC-122 A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE) Active, not recruiting
NCT02747043 Phase III ABP 798 Rituximab Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE) Active, not recruiting
NCT03136146 Phase II Cyclophosphamide Bortezomib Etoposide Rituximab Ofatumumab Clofarabine Pegfilgrastim Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) Recruiting
NCT02733042 Phase Ib/II Rituximab lenalidomide + MEDI4736 + Rituximab Bendamustine + MEDI4736 + Rituximab Ibrutinib + MEDI4736 Durvalumab A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) Active, not recruiting
NCT02531308 Phase II Metformin Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Pegfilgrastim Rituximab Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) Terminated
NCT03150693 Phase III Rituximab Doxorubicin Mercaptopurine Methotrexate Cyclophosphamide + Cytarabine Thioguanine Allopurinol Daunorubicin Dexamethasone Vincristine inotuzumab ozogamicin Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia Recruiting
NCT03418038 Phase II Dexamethasone Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Rituximab Cytarabine + Dexamethasone + Oxaliplatin Gemcitabine + Oxaliplatin Cisplatin + Cytarabine + Dexamethasone + Rituximab Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma Recruiting
NCT02205333 Phase Ib/II Rituximab MEDI6469 Tremelimumab Durvalumab A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies Terminated
NCT01686165 Phase II Belinostat Rituximab Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Completed
NCT00577278 Phase II Ibritumomab Sirolimus + Tacrolimus + Methotrexate Rituximab Fludarabine + Melphalan Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma Active, not recruiting
NCT03609593 Phase II Rituximab Bendamustine + Rituximab Venetoclax Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia Not yet recruiting
NCT02626455 Phase III Vincristine Prednisone Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine Copanlisib Bendamustine + Rituximab Rituximab Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) Recruiting
NCT02055820 Phase I Venetoclax Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Obinutuzumab A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma Active, not recruiting
NCT02031419 Phase I CC-122 + CC-292 CC-223 + CC-292 CC-122 + CC-223 Rituximab Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma Active, not recruiting
NCT02003222 Phase III Cytarabine Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Mercaptopurine + Methotrexate + Prednisone + Vincristine Cyclophosphamide + Cytarabine + Mercaptopurine + Pegaspargase Methotrexate + Pegaspargase Cytarabine + Etoposide + Methotrexate Rituximab Blinatumomab Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Recruiting
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Recruiting
NCT03147612 Phase II Mesna Vincristine Dexamethasone Rituximab Filgrastim Ponatinib Cyclophosphamide Methotrexate Cytarabine Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Recruiting
NCT02018861 Phase I Itacitinib INCB039110 + INCB050465 Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide INCB050465 A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting
NCT02007044 Phase II Ibrutinib Rituximab Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) Active, not recruiting
NCT02538926 Phase II Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Asparaginase Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Withdrawn
NCT03571321 Phase I Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Ruxolitinib Cyclophosphamide Dexamethasone Vincristine Rituximab Doxorubicin Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Not yet recruiting
NCT02337985 Phase I Rituximab Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Filgrastim Prednisone Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting
NCT02203526 Phase I Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib Cytarabine Rituximab Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma Recruiting
NCT01453205 Phase II Cisplatin + Cytarabine + Dexamethasone Carboplatin + Etoposide + Ifosfamide Rituximab MEDI-551 A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed
NCT03023046 Phase II Rituximab Doxorubicin Etoposide Imatinib Dasatinib Cyclophosphamide Prednisone Vincristine Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting
NCT00092222 Phase II Sirolimus Alpha 2 Interferon EPOCH Rituximab Bortezomib Doxil Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Recruiting
NCT00114738 Phase II R-EPOCH Rituximab Bortezomib EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma Active, not recruiting
NCT00878254 Phase II R-MACLO/IVAM Rituximab Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma Recruiting
NCT01619761 Phase I Rituximab lenalidomide + Fludarabine + Melphalan Mycophenolate mofetil Tacrolimus Natural Killer (NK) Cells in Cord Blood Transplantation Recruiting
NCT00267865 Phase II Rituximab Methotrexate Leucovorin Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma Recruiting
NCT03267433 Phase III Rituximab Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Recruiting
NCT01871675 Phase I Rituximab Duvelisib Bendamustine Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Completed
NCT01992653 Phase I Cyclophosphamide + Doxorubicin + Prednisone Rituximab Polatuzumab Vedotin Obinutuzumab A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma Completed
NCT01983969 Phase Ib/II Rituximab Dexamethasone Busulfan + Melphalan Azacitidine + Gemcitabine + vorinostat Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed
NCT02367040 Phase III Rituximab Copanlisib Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) Recruiting
NCT01326702 Phase Ib/II Veliparib Rituximab Bendamustine Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed
NCT02005471 Phase III Venetoclax Bendamustine Rituximab A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Active, not recruiting
NCT02043587 Phase II Rituximab Pegaspargase Methotrexate Cytarabine Leucovorin Cyclophosphamide Dasatinib Daunorubicin Vincristine Etoposide Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma Active, not recruiting
NCT01319981 Phase II Pegfilgrastim Imatinib Filgrastim Rituximab Doxorubicin Dexamethasone Vincristine Cyclophosphamide Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia Active, not recruiting
NCT02204982 Phase III Duvelisib Rituximab Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R) Terminated
NCT02423915 Phase Ib/II Filgrastim Rituximab Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention Active, not recruiting
NCT00074490 Phase II Cyclophosphamide Cyclosporine Rituximab Doxorubicin Etoposide Filgrastim Vincristine Fludarabine Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Terminated
NCT03117751 Phase II Cyclophosphamide Vincristine Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting
NCT01371630 Phase Ib/II inotuzumab ozogamicin Ara-C + Cyclophosphamide + Inotuzumab ozogamicin + Methotrexate + Vincristine Mercaptopurine + Methotrexate + Prednisone + Vincristine Rituximab Cytarabine + Inotuzumab ozogamicin + Methotrexate Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Acute Lymphoblastic Leukemia Recruiting
NCT01701986 Phase Ib/II Tacrolimus Rituximab Filgrastim Mycophenolate mofetil anti-thymocyte globulin Busulfan + Clofarabine + Gemcitabine Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas Recruiting
NCT02484053 Phase I Rituximab Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders Completed
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting
NCT01855750 Phase III Ibrutinib Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT02589145 Phase Ib/II Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Active, not recruiting
NCT02541565 Phase I Pembrolizumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Rituximab Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma Recruiting
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Sirolimus + Tacrolimus + Methotrexate Doxorubicin + Etoposide + Fludarabine + Vincristine Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting
NCT01415752 Phase II Bortezomib Bendamustine Rituximab Lenalidomide Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma Recruiting
NCT02532192 Phase I Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma Withdrawn
NCT02408042 Phase Ib/II Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) Withdrawn
NCT03488225 Phase II Mercaptopurine + Methotrexate + Prednisone + Vincristine Methotrexate + Cytarabine + Leucovorin inotuzumab ozogamicin Ofatumumab Rituximab Cytarabine + Doxorubicin + Methotrexate + Vincristine Pegfilgrastim Cyclophosphamide + Dexamethasone + Mesna Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia Recruiting
NCT01732913 Phase III Idelalisib Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated
NCT01665768 Phase II Rituximab Everolimus Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Active, not recruiting